Research and Clinical Trials

Brief Description  
To evaluate the effectiveness and safety of BAF312 compred to placebo (a substance that looks like BAF312 but does not contain any active ingredient) in people with secondary progressive multiple sclerosis (SPMS). Your participation will last for 23 to 42 months, but no more than 60 months, depending on when you enroll in the study. You would be randomized (put in a group by a chance process, like flipping a coin) to receive either BAF312 or placebo. BAF312.
Who may be Eligible  
18-60 years of age; documented clinical diagnosis of SPMS; EDSS score of 3.0-6.5r; disability progression in the previous 2 years; no evidence of relapse or corticosteroid treatment 3 months prior to entering the study.
Multiple Sclerosis
Start Date  
IRB Number  
Principal Investigator  
Conway, Jill
Contact Name  
Bridget Loven
Alternate Phone  
(704) 446-1909

For More Information, Contact   Bridget  Loven
Phone:  (704) 446-1987  Fax:  (704) 446-1915 
Address:  Carolinas Medical Center - Department of Neurology
1010 Edgehill Road, North
Charlotte, NC 28207